Company news
Terns Pharmaceuticals, Inc. news in 2024
Terns Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
December 2, 2024
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
November 17, 2024
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
November 11, 2024
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
November 5, 2024
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 11, 2024
Terns Announces Pricing of Upsized $150.15 Million Public Offering
September 9, 2024
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
September 8, 2024
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
August 4, 2024
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
July 28, 2024
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
June 20, 2024
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
May 16, 2024
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
May 12, 2024
Terns Pharmaceuticals Announces Leadership Changes
May 7, 2024
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
May 6, 2024
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
April 28, 2024
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
April 9, 2024
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 13, 2024
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
March 10, 2024
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 26, 2024
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
February 6, 2024
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
February 6, 2024
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024